Adrian Percer

Specialty / focus areas. Adrian Percer is a trial and post-grant patent litigator whose tracked matters span wireless/telecommunications standards (e.g., XiFi Networks v. Samsung, involving IEEE 802.11be/Wi-Fi 7 multi-link operation), pharmaceutical/biotech chemistry (Halozyme v. Merck, involving hyaluronidase enzyme patents for subcutaneous Keytruda), software and e-commerce, digital rights management, smartphone technologies, imaging, and medical devices. His Weil/WilmerHale bios describe a technical background in mechanical engineering and case work across wireless communication, distributed computing, cybersecurity, DRM, and medical device technologies.

Side preference. He is overwhelmingly defense-side: four of his five tracked appearances are for defendants (Samsung, Merck/MSD, Visa, Tesla), with one plaintiff-side matter. His practice centers on defending operating companies — largely against NPE/PAE assertions (Tesla, Samsung, Visa) and in competitor disputes (Merck/MSD), rather than prosecuting patents for monetizers.

Firm context. Percer spent nearly 24 years at Weil, Gotshal & Manges (associate from 2001, appointed counsel in 2010, later partner in the Silicon Valley office) before joining WilmerHale's IP practice in Palo Alto in July 2025. Per the tracking data, one matter (Cortex MCP, Inc. v. Visa, Inc.) is attributed to Latham & Watkins; that attribution could not be independently verified through public sources, which otherwise place him at Weil for his entire career to date.

Notable cases / outcomes. Tracked highlights: lead counsel for Merck/MSD in Halozyme v. Merck (D.N.J., filed Apr. 2025), a high-stakes dispute over the subcutaneous Keytruda formulation, with seven Merck PGR petitions pending and parallel litigation in the UK and Germany; Lead Counsel for Tesla in Autonomous Devices, LLC v. Tesla (D. Del.), with Tesla also petitioning for IPR of the asserted patents; counsel for Samsung in XiFi Networks v. Samsung (E.D. Tex.), where Samsung's eight IPR and three PGR petitions were all instituted in December 2025. Firm-published results include PTAB invalidity findings affirmed by the Federal Circuit (PayPal; Adobe/EA DRM jury verdict of invalidity affirmed on appeal), defense of a ~$3B eBay damages claim via PTAB invalidity, a complete ITC win for a smartphone client, and the 2023 Synthego PTAB victory invalidating Agilent's CRISPR patents.

PTAB / IPR experience. Extensive — Weil described him as "regularly recognized as one of the most active attorneys before the PTAB," with participation in more than 125 IPR proceedings, and he has managed 20+ post-grant proceedings in individual cases (e.g., NuMark). Bar / education: California bar (2001), USPTO Reg. No. 46,986, N.D. Cal.; B.S. mechanical engineering, MIT (1996); M.S. mechanical engineering, Stanford (1998); J.D., Santa Clara University School of Law (2001).